SANA BIOTECHNOLOGY INC (SANA) Stock Price, Quote, News and Overview
NASDAQ:SANA - Nasdaq - US7995661045 - Common Stock - Currency: USD
SANA Quote, Performance and Key Statistics
SANA BIOTECHNOLOGY INC
NASDAQ:SANA (2/10/2025, 8:22:00 PM)
Premarket: 2.75 +0.02 (+0.55%)2.735
-0.26 (-8.53%)
The current stock price of SANA is 2.735 USD. In the past month the price decreased by -25.27%. In the past year, price decreased by -68.49%.
SANA Latest News and Analysis
Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why
Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.
There May Still Be Time to Get in on These 3 Trending Biotechs
Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.
Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through...
SANA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.81 | 336.36B | ||
| AMGN | AMGEN INC | 14.87 | 158.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1620.59 | 121.03B | ||
| GILD | GILEAD SCIENCES INC | 21.55 | 118.99B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.13 | 75.86B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.66B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.35B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.63B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.41B | ||
| NTRA | NATERA INC | N/A | 22.73B | ||
| BIIB | BIOGEN INC | 8.73 | 20.77B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.18 | 15.43B |
Related stock screener links
About SANA
Company Profile
Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. The company is headquartered in Seattle, Washington and currently employs 328 full-time employees. The company went IPO on 2021-02-04. The company is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. The company develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC291, SC262, SC255, C379, SC451 and UP421. The company is applying its hypoimmune technology to donor derived T cells to be used as allogeneic cell therapies for hematologic malignancies. The company is developing SC255, a B-cell maturation antigen-directed allogeneic CAR T, for the treatment of multiple myeloma. The company is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B-cell malignancies.
Company Info
SANA BIOTECHNOLOGY INC
188 East Blaine Street, Suite 400
Seattle WASHINGTON 98102 US
CEO: Steven D. Harr
Employees: 328
Company Website: https://sana.com/
Investor Relations: https://ir.sana.com/
Phone: 12067017914
SANA FAQ
What is the stock price of SANA?
The current stock price of SANA is 2.735 USD.
What is the symbol for SANA BIOTECHNOLOGY INC stock?
The exchange symbol of SANA BIOTECHNOLOGY INC is SANA and it is listed on the Nasdaq exchange.
On which exchange is SANA stock listed?
SANA stock is listed on the Nasdaq exchange.
Is SANA a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for SANA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of SANA.
Does SANA stock pay dividends?
SANA does not pay a dividend.
What is the Price/Earnings (PE) ratio of SANA?
SANA does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.36).
What is the Short Interest ratio of SANA stock?
The outstanding short interest for SANA is 24.72% of its float.
SANA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to SANA. When comparing the yearly performance of all stocks, SANA is a bad performer in the overall market: 90.25% of all stocks are doing better.
SANA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SANA. SANA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SANA Financial Highlights
Over the last trailing twelve months SANA reported a non-GAAP Earnings per Share(EPS) of -1.36. The EPS decreased by 1.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.67% | ||
| ROE | -104.56% | ||
| Debt/Equity | 0 |
SANA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to SANA. The Buy consensus is the average rating of analysts ratings from 13 analysts.